Randomized Phase III Trial of Erlotinib versus Docetaxel in Patients with Advanced Squamous Cell Non–Small Cell Lung Cancer Failing First-Line Platinum-Based Doublet Chemotherapy Stratified by VeriStrat Good versus VeriStrat Poor. The European Thoracic Oncology Platform (ETOP) EMPHASIS-lung Trial

S Peters, RA Stahel, U Dafni, S Ponce Aix, B Massutí, O Gautschi, L Coate, A López Martín, R van Heemst, T Berghmans, P Meldgaard, M Cobo Dols, J Garde Noguera, A Curioni-Fontecedro, D Rauch, MT Mark, S Cuffe, B Biesma, AMJ van Henten, Ó Juan VidalR Palmero Sanchez, JC Villa Guzmán, R Collado Martin, S Peralta, A Insa, Y Summers, I Láng, A Horgan, F Ciardiello, S de Hosson, R Pieterman, HJM Groen, PM van den Berg, CC Zielinski, Y Chittazhathu Kurian Kuruvilla, A Gasca-Ruchti, M Kassapian, S Novello, V Torri, Z Tsourti, V Gregorc, EF Smit, for the EMPHASIS-lung Collaborative Group

Research output: Contribution to journal › Article › peer-review

Fingerprint

Dive into the research topics of 'Randomized Phase III Trial of Erlotinib versus Docetaxel in Patients with Advanced Squamous Cell Non–Small Cell Lung Cancer Failing First-Line Platinum-Based Doublet Chemotherapy Stratified by VeriStrat Good versus VeriStrat Poor. The European Thoracic Oncology Platform (ETOP) EMPHASIS-lung Trial'. Together they form a unique fingerprint.

Medicine & Life Sciences